150 related articles for article (PubMed ID: 12020594)
1. Comparative effect of colchicine and colchiceine on cytotoxicity and CYP gene expression in primary human hepatocytes.
Dvorak Z; Ulrichova J; Pichard-Garcia L; Modriansky M; Maurel P
Toxicol In Vitro; 2002 Jun; 16(3):219-27. PubMed ID: 12020594
[TBL] [Abstract][Full Text] [Related]
2. Effect of colchicine and its derivatives on the expression of selected isoforms of cytochrome P450 in primary cultures of human hepatocytes.
Dvorák Z; Ulrichová J; Modrianský M; Maurel P
Acta Univ Palacki Olomuc Fac Med; 2000; 143():47-50. PubMed ID: 11144118
[TBL] [Abstract][Full Text] [Related]
3. Expression and transcriptional activities of nuclear receptors involved in regulation of drug-metabolizing enzymes are not altered by colchicine: focus on PXR, CAR, and GR in primary human hepatocytes.
Dvorák Z; Maurel P; Vilarem MJ; Ulrichová J; Modrianský M
Cell Biol Toxicol; 2007 Mar; 23(2):63-73. PubMed ID: 16964586
[TBL] [Abstract][Full Text] [Related]
4. Assessment of induction of cytochrome P450 by NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, in primary cultures of human hepatocytes and in female rat liver.
Morioka Y; Nishimura M; Imai T; Suzuki S; Harada M; Satoh T; Naito S
Drug Metab Pharmacokinet; 2006 Feb; 21(1):19-28. PubMed ID: 16547390
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.
Wu Y; Chitranshi P; Loukotková L; Gamboa da Costa G; Beland FA; Zhang J; Fang JL
Arch Toxicol; 2017 Jun; 91(6):2405-2423. PubMed ID: 27896399
[TBL] [Abstract][Full Text] [Related]
7. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities.
Doehmer J; Weiss G; McGregor GP; Appel K
Toxicol In Vitro; 2011 Feb; 25(1):21-7. PubMed ID: 20828605
[TBL] [Abstract][Full Text] [Related]
8. Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation.
Dvorak Z; Modriansky M; Pichard-Garcia L; Balaguer P; Vilarem MJ; Ulrichová J; Maurel P; Pascussi JM
Mol Pharmacol; 2003 Jul; 64(1):160-9. PubMed ID: 12815172
[TBL] [Abstract][Full Text] [Related]
9. Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro.
Shimokawa Y; Sasahara K; Yoda N; Mizuno K; Umehara K
Biol Pharm Bull; 2014; 37(11):1727-35. PubMed ID: 25366478
[TBL] [Abstract][Full Text] [Related]
10. Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy.
Danek PJ; Wójcikowski J; Daniel WA
Toxicol Appl Pharmacol; 2020 Nov; 406():115239. PubMed ID: 32941854
[TBL] [Abstract][Full Text] [Related]
11. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
Parkinson A; Mudra DR; Johnson C; Dwyer A; Carroll KM
Toxicol Appl Pharmacol; 2004 Sep; 199(3):193-209. PubMed ID: 15364537
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
13. Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up.
Meunier V; Bourrié M; Julian B; Marti E; Guillou F; Berger Y; Fabre G
Xenobiotica; 2000 Jun; 30(6):589-607. PubMed ID: 10923861
[TBL] [Abstract][Full Text] [Related]
14. Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms.
Kim J; Peraire C; Solà J; Johanning KM; Dalton JT; Veverka KA
Xenobiotica; 2011 Oct; 41(10):851-62. PubMed ID: 21726172
[TBL] [Abstract][Full Text] [Related]
15. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology.
Yoshitomi S; Ikemoto K; Takahashi J; Miki H; Namba M; Asahi S
Toxicol In Vitro; 2001 Jun; 15(3):245-56. PubMed ID: 11377097
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of 2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin by human hepatic CYP isoforms: evidence for selectivity towards CYP3A4.
Renwick AB; Lewis DF; Fulford S; Surry D; Williams B; Worboys PD; Cai X; Wang RW; Price RJ; Lake BG; Evans DC
Xenobiotica; 2001 Apr; 31(4):187-204. PubMed ID: 11465405
[TBL] [Abstract][Full Text] [Related]
17. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist.
Takusagawa S; Miyashita A; Iwatsubo T; Usui T
Xenobiotica; 2012 Dec; 42(12):1187-96. PubMed ID: 22834478
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
19. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
20. Enzyme induction and cytotoxicity in human hepatocytes by chlorpyrifos and N,N-diethyl-m-toluamide (DEET).
Das PC; Cao Y; Rose RL; Cherrington N; Hodgson E
Drug Metabol Drug Interact; 2008; 23(3-4):237-60. PubMed ID: 19326769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
